Instructions for use
The Galaxy System™ and its accessories are intended to provide bronchoscopic visualization of and access to patient airways for diagnostic and therapeutic procedures.
This information is for Galaxy System customers only. Please do not share. To access the Galaxy System™ Instructions For Use click the link below.
Download PDF Software version 1.0.1.0
Download PDF Software version 1.0.2.0
“The ability to be able to toss the scope at the end of each case reduces the burden on my team and improves turnover times.”
- Krish Bhadra, MD
Building a Robotic Lung Biopsy Program
Detection, diagnosis and treatment of early-stage lung cancer saves lives. Learn how your institution can increase procedural volume and revenue, avoid significant capital expenditure to correct for CT-to-body divergence, reduce the risk of cross-contamination and avoid the hidden costs of reprocessing bronchoscopes with the Galaxy System™, the next generation, image-integrated robotic-assisted bronchoscopy (iiRAB) solution.
Comparison of Disposable vs. Reusable Robotic Bronchoscopes
Single-use disposable bronchoscopes offer several advantages over reusable bronchoscopes. To learn more about the hidden costs of reprocessing bronchoscopes, the risk of cross-contamination and its associated treatment costs as well as the environmental impact of reprocessing bronchoscopes, click on the button below.
Impact of Early Diagnosis in Lung Cancer
Early detection of lung cancer offers several clinical and economic benefits. A combination of patient education, multi-disciplinary integrated lung nodule programs and the use of advanced imaging-integrated robotic-assisted biopsy technologies can help identify, diagnose and treat lung cancer at an earlier stage and improve clinical outcomes for patients while relieving some of the economic burden associated with lung cancer.
The Galaxy Experience: First 90 Cases
Dr. Hogarth provides insights from the first 90 Galaxy System procedures he and his staff performed at UChicago Medicine. Of the 110 lesions investigated in 90 patients, almost 90% were located in the outer 1/3rd or pleura, and over 80% of them were less than 2cm in size. Despite the challenging locations and size, Dr Hogarth was able to secure a 92% to 96% diagnostic yield.
The Galaxy Experience: First 75 Cases
Dr. Mahajan provides insights from the first 75 Galaxy System procedures he and his staff performed at Inova Fairfax Hospital. The lesions averaged 14mm in size, and almost 75% of them were located in the outer 1/3rd or pleura. Despite the challenging locations and size, Dr Mahajan was able to secure a 96% diagnostic yield.
